Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 8901SC

8901SC 100 µg (With Carrier) $269.00
8901SF 100 µg (Carrier Free) $269.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IFN-γ (hIFN-γ) Gln24-Gln166 (Accession # NM_000619) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>96% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIFN-γ. All lots are greater than 96% pure.


Molecular Formula:

Recombinant hIFN-γ has a Met on the amino terminus and has a calculated MW of 16,907. DTT-reduced and non-reduced protein migrate as 17 kDa polypeptides. The expected amino-terminus MQDPY of recombinant hIFN-γ was verified by amino acid sequencing.


Bioactivity:

The bioactivity of hIFN-γ was determined in a virus protection assay. The ED50 of each lot is between 0.30-1.2 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIFN-γ.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIFN-γ. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 with trehalose.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months. Maintain Sterility. Do not store frozen.

IFN-γ plays key roles in both the innate and adaptive immune response. IFN-γ activates the cytotoxic activity of innate immune cells such as macrophages and NK cells (1,2). IFN-γ production by NK cells and antigen-presenting cells (APCs) promotes the cell mediated adaptive immunity by inducing IFN-γ production by T lymphocytes, increased class I and class II MHC expression, and enhancing peptide antigen presentation (1). The anti-viral activity of IFN-γ is due to its induction of PKR and other regulatory proteins. Binding of IFN-γ to the IFNGR1/IFNGR2 complex promotes dimerization of the receptor complexes to form (IFNGR1/IFNGR2)2 -IFN-γ dimer. Binding induces a conformational change in receptor intracellular domains and signaling involves Jak1, Jak2 and Stat1 (3). The critical role of IFN-γ in amplification of immune surveillance and function is supported by increased susceptibility to pathogen infection by IFN-γ or IFNGR knockout mice and in humans with inactivating mutations in IFNGR1 or IFNGR2. IFN-γ also appears to have a role in atherosclerosis (4).


1.  Schroder, K. et al. (2004) J Leukoc Biol 75, 163-89.

2.  Martinez, F.O. et al. (2009) Annu Rev Immunol 27, 451-83.

3.  Kotenko, S.V. et al. (1995) J Biol Chem 270, 20915-21.

4.  McLaren, J.E. and Ramji, D.P. (2009) Cytokine Growth Factor Rev 20, 125-35.


Entrez-Gene Id 3458
Swiss-Prot Acc. P01579


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.